120 related articles for article (PubMed ID: 30474459)
1. Pre-formulation investigations for establishing a protocol for treosulfan handling and activation.
El-Serafi I; Loy O; Zhao Y; Oerther S; Mattsson J
Pharm Dev Technol; 2019 Jun; 24(5):639-648. PubMed ID: 30474459
[TBL] [Abstract][Full Text] [Related]
2. DNA alkylation and interstrand cross-linking by treosulfan.
Hartley JA; O'Hare CC; Baumgart J
Br J Cancer; 1999 Jan; 79(2):264-6. PubMed ID: 9888467
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of in Vitro Guanine- N7-Alkylation in Calf Thymus DNA by (2 S,3 S)-1,2-Epoxybutane-3,4-diol 4-methanesulfonate and (2 S,3 S)-1,2:3,4-Diepoxybutane: Revision of the Mechanism of DNA Cross-Linking by the Prodrug Treosulfan.
Romański M; Pogorzelska A; Główka FK
Mol Pharm; 2019 Jun; 16(6):2708-2718. PubMed ID: 31013419
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
Munkelt D; Koehl U; Kloess S; Zimmermann SY; Kalaäoui RE; Wehner S; Schwabe D; Lehrnbecher T; Schubert R; Kreuter J; Klingebiel T; Esser R
Cancer Chemother Pharmacol; 2008 Oct; 62(5):821-30. PubMed ID: 18246351
[TBL] [Abstract][Full Text] [Related]
5. N-7-Guanine Adduct of the Active Monoepoxide of Prodrug Treosulfan: First Synthesis, Characterization, and Decomposition Profile Under Physiological Conditions.
Romański M; Girreser U; Teżyk A; Główka FK
J Pharm Sci; 2018 Nov; 107(11):2927-2937. PubMed ID: 29960026
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effects of treosulfan on prostate cancer cell lines.
Feyerabend S; Feil G; Krug J; Kassen A; Stenzl A
Anticancer Res; 2007; 27(4B):2403-8. PubMed ID: 17695531
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Red Blood Cells/Plasma Partition Coefficient of Treosulfan and Its Active Monoepoxide in Rats.
Romański M; Zacharzewska A; Teżyk A; Główka FK
Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):565-571. PubMed ID: 29542019
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
Lanvers-Kaminsky C; Bremer A; Dirksen U; Jürgens H; Boos J
Anticancer Drugs; 2006 Jul; 17(6):657-62. PubMed ID: 16917211
[TBL] [Abstract][Full Text] [Related]
9. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.
Bhagwatwar HP; Phadungpojna S; Chow DS; Andersson BS
Cancer Chemother Pharmacol; 1996; 37(5):401-8. PubMed ID: 8599861
[TBL] [Abstract][Full Text] [Related]
10. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation.
Główka FK; Łada MK; Grund G; Wachowiak J
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):569-74. PubMed ID: 17210272
[TBL] [Abstract][Full Text] [Related]
11. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro.
Köpf-Maier P
In Vivo; 1998; 12(3):275-88. PubMed ID: 9706471
[TBL] [Abstract][Full Text] [Related]
12. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
Główka FK; Romański M; Wachowiak J
Expert Opin Investig Drugs; 2010 Oct; 19(10):1275-95. PubMed ID: 20836619
[TBL] [Abstract][Full Text] [Related]
13. Activation of Prodrug Treosulfan at pH 7.4 and 37°C Accompanied by Hydrolysis of Its Active Epoxides: Kinetic Studies with Clinical Relevance.
Romański M; Urbaniak B; Kokot Z; Główka FK
J Pharm Sci; 2015 Dec; 104(12):4433-4442. PubMed ID: 26422826
[TBL] [Abstract][Full Text] [Related]
14. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.
ten Brink MH; Zwaveling J; Swen JJ; Bredius RG; Lankester AC; Guchelaar HJ
Drug Discov Today; 2014 Oct; 19(10):1572-86. PubMed ID: 24747172
[TBL] [Abstract][Full Text] [Related]
15. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer.
Hilger RA; Jacek G; Oberhoff C; Kredtke S; Baumgart J; Seeber S; Scheulen ME
Cancer Chemother Pharmacol; 2000; 45(6):483-8. PubMed ID: 10854136
[TBL] [Abstract][Full Text] [Related]
16. Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives.
Romański M; Wachowiak J; Główka FK
Clin Pharmacokinet; 2018 Oct; 57(10):1255-1265. PubMed ID: 29557088
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients.
Meinhardt G; Dayyani F; Jahrsdörfer B; Baumgart J; Emmerich B; Schmidmaier R
Br J Haematol; 2003 Sep; 122(6):892-9. PubMed ID: 12956758
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo.
Neuber K; tom Dieck A; Blödorn-Schlicht N; Itschert G; Karnbach C
Melanoma Res; 1999 Apr; 9(2):125-32. PubMed ID: 10380934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
